Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Stability of Hydromorphone-Ketamine Solutions in Glass Bottles, Plastic Syringes, and IV Bags for Pediatric Use.

The Canadian journal of hospital pharmacy

Ensom MH, Decarie D, Leung K, Montgomery C.
PMID: 22478876
Can J Hosp Pharm. 2009 Mar;62(2):112-8. doi: 10.4212/cjhp.v62i2.439.

OBJECTIVES: To evaluate the stability of mixtures of hydromorphone and ketamine in 0.9% sodium chloride (normal saline [NS]) after storage for up to 7 days at room temperature (25°C).METHODS: The stability of 3 standard mixtures of hydromorphone and ketamine...

Cite
Ensom MH, Decarie D, Leung K, et al. Stability of Hydromorphone-Ketamine Solutions in Glass Bottles, Plastic Syringes, and IV Bags for Pediatric Use. Can J Hosp Pharm. 2009;62(2):112-8doi: 10.4212/cjhp.v62i2.439.
Ensom, M. H., Decarie, D., Leung, K., & Montgomery, C. (2009). Stability of Hydromorphone-Ketamine Solutions in Glass Bottles, Plastic Syringes, and IV Bags for Pediatric Use. The Canadian journal of hospital pharmacy, 62(2), 112-8. https://doi.org/10.4212/cjhp.v62i2.439
Ensom, Mary H H, et al. "Stability of Hydromorphone-Ketamine Solutions in Glass Bottles, Plastic Syringes, and IV Bags for Pediatric Use." The Canadian journal of hospital pharmacy vol. 62,2 (2009): 112-8. doi: https://doi.org/10.4212/cjhp.v62i2.439
Ensom MH, Decarie D, Leung K, Montgomery C. Stability of Hydromorphone-Ketamine Solutions in Glass Bottles, Plastic Syringes, and IV Bags for Pediatric Use. Can J Hosp Pharm. 2009 Mar;62(2):112-8. doi: 10.4212/cjhp.v62i2.439. PMID: 22478876; PMCID: PMC2826933.
Copy Download .nbib Format: NLM
Stability of propranolol in extemporaneously compounded suspensions.

The Canadian journal of hospital pharmacy

Ensom MH, Kendrick J, Rudolph S, Decarie D.
PMID: 23616676
Can J Hosp Pharm. 2013 Mar;66(2):118-24. doi: 10.4212/cjhp.v66i2.1234.

BACKGROUND: Propranolol is a drug of choice for many diseases occurring in neonates and infants, an age group for which oral suspensions are required almost exclusively. Many adult and elderly patients for whom propranolol is prescribed are also unable...

Cite
Ensom MH, Kendrick J, Rudolph S, et al. Stability of propranolol in extemporaneously compounded suspensions. Can J Hosp Pharm. 2013;66(2):118-24doi: 10.4212/cjhp.v66i2.1234.
Ensom, M. H., Kendrick, J., Rudolph, S., & Decarie, D. (2013). Stability of propranolol in extemporaneously compounded suspensions. The Canadian journal of hospital pharmacy, 66(2), 118-24. https://doi.org/10.4212/cjhp.v66i2.1234
Ensom, Mary H H, et al. "Stability of propranolol in extemporaneously compounded suspensions." The Canadian journal of hospital pharmacy vol. 66,2 (2013): 118-24. doi: https://doi.org/10.4212/cjhp.v66i2.1234
Ensom MH, Kendrick J, Rudolph S, Decarie D. Stability of propranolol in extemporaneously compounded suspensions. Can J Hosp Pharm. 2013 Mar;66(2):118-24. doi: 10.4212/cjhp.v66i2.1234. PMID: 23616676; PMCID: PMC3633496.
Copy Download .nbib Format: NLM
Assessing explicit processes does not influence the magnitude of implicit processes.

Neuroscience letters

Moghaddam SH, Decarie A, Chua R, Cressman EK.
PMID: 34801641
Neurosci Lett. 2022 Jan 01;766:136341. doi: 10.1016/j.neulet.2021.136341. Epub 2021 Nov 18.

Implicit (unconscious) and explicit (strategy) processes have been shown to contribute to visuomotor adaptation. Current methods, such as the Process Dissociation Procedure (PDP) and the Verbal Report Framework (VRF), simultaneously evaluate both implicit and explicit contributions to visuomotor adaptation....

Cite
Moghaddam SH, Decarie A, Chua R, et al. Assessing explicit processes does not influence the magnitude of implicit processes. Neurosci Lett. 2021;766:136341doi: 10.1016/j.neulet.2021.136341.
Moghaddam, S. H., Decarie, A., Chua, R., & Cressman, E. K. (2022). Assessing explicit processes does not influence the magnitude of implicit processes. Neuroscience letters, 766136341. https://doi.org/10.1016/j.neulet.2021.136341
Moghaddam, S Heirani, et al. "Assessing explicit processes does not influence the magnitude of implicit processes." Neuroscience letters vol. 766 (2022): 136341. doi: https://doi.org/10.1016/j.neulet.2021.136341
Moghaddam SH, Decarie A, Chua R, Cressman EK. Assessing explicit processes does not influence the magnitude of implicit processes. Neurosci Lett. 2022 Jan 01;766:136341. doi: 10.1016/j.neulet.2021.136341. Epub 2021 Nov 18. PMID: 34801641.
Copy Download .nbib Format: NLM
Management of Tennis Elbow with sodium hyaluronate periarticular injections.

Sports medicine, arthroscopy, rehabilitation, therapy & technology : SMARTT

Petrella RJ, Cogliano A, Decaria J, Mohamed N, Lee R.
PMID: 20205851
Sports Med Arthrosc Rehabil Ther Technol. 2010 Feb 02;2:4. doi: 10.1186/1758-2555-2-4.

OBJECTIVES: To determine the efficacy and safety of peri-articular hyaluronic acid injections in chronic lateral epicondylosis (tennis elbow).DESIGN: Prospective randomized clinical trial in primary care sport medicine.PATIENTS: Three hundred and thirty one consecutive competitive racquette sport athletes with chronic...

Cite
Petrella RJ, Cogliano A, Decaria J, et al. Management of Tennis Elbow with sodium hyaluronate periarticular injections. Sports Med Arthrosc Rehabil Ther Technol. 2010;2:4doi: 10.1186/1758-2555-2-4.
Petrella, R. J., Cogliano, A., Decaria, J., Mohamed, N., & Lee, R. (2010). Management of Tennis Elbow with sodium hyaluronate periarticular injections. Sports medicine, arthroscopy, rehabilitation, therapy & technology : SMARTT, 24. https://doi.org/10.1186/1758-2555-2-4
Petrella, Robert J, et al. "Management of Tennis Elbow with sodium hyaluronate periarticular injections." Sports medicine, arthroscopy, rehabilitation, therapy & technology : SMARTT vol. 2 (2010): 4. doi: https://doi.org/10.1186/1758-2555-2-4
Petrella RJ, Cogliano A, Decaria J, Mohamed N, Lee R. Management of Tennis Elbow with sodium hyaluronate periarticular injections. Sports Med Arthrosc Rehabil Ther Technol. 2010 Feb 02;2:4. doi: 10.1186/1758-2555-2-4. PMID: 20205851; PMCID: PMC2825499.
Copy Download .nbib Format: NLM
Stability of levetiracetam in extemporaneously compounded suspensions.

The Canadian journal of hospital pharmacy

Ensom MH, Decarie D, Rudolph S.
PMID: 22479056
Can J Hosp Pharm. 2011 May;64(3):207-11. doi: 10.4212/cjhp.v64i3.1024.

BACKGROUND: Levetiracetam is widely used as adjunctive therapy in the treatment of partial-onset seizures, myoclonic seizures, primary generalized tonic-clonic seizures, and idiopathic generalized epilepsy in the community and in hospital. However, no convenient, easy-to-swallow dosage form is commercially available...

Cite
Ensom MH, Decarie D, Rudolph S. Stability of levetiracetam in extemporaneously compounded suspensions. Can J Hosp Pharm. 2011;64(3):207-11doi: 10.4212/cjhp.v64i3.1024.
Ensom, M. H., Decarie, D., & Rudolph, S. (2011). Stability of levetiracetam in extemporaneously compounded suspensions. The Canadian journal of hospital pharmacy, 64(3), 207-11. https://doi.org/10.4212/cjhp.v64i3.1024
Ensom, Mary H H, et al. "Stability of levetiracetam in extemporaneously compounded suspensions." The Canadian journal of hospital pharmacy vol. 64,3 (2011): 207-11. doi: https://doi.org/10.4212/cjhp.v64i3.1024
Ensom MH, Decarie D, Rudolph S. Stability of levetiracetam in extemporaneously compounded suspensions. Can J Hosp Pharm. 2011 May;64(3):207-11. doi: 10.4212/cjhp.v64i3.1024. PMID: 22479056; PMCID: PMC3130756.
Copy Download .nbib Format: NLM
Multiple host-specificity loci of the broad host-range Rhizobium sp. NGR234 selected using the widely compatible legume Vigna unguiculata.

Plant molecular biology

Lewin A, Rosenberg C, H Meyer ZA, Wong CH, Nelson L, Manen JF, Stanley J, Dowling DN, Denarie J, Broughton WJ.
PMID: 24301307
Plant Mol Biol. 1987 Nov;8(6):447-59. doi: 10.1007/BF00017990.

Specificity in legume-Rhizobium symbiosis depends on plant and rhizobial genes. As our objective was to study broad host-range determinants of rhizobia, we sought a legume and a Rhizobium with the lowest possible specificity. By inoculating 12 different legumes with...

Cite
Lewin A, Rosenberg C, H Meyer ZA, et al. Multiple host-specificity loci of the broad host-range Rhizobium sp. NGR234 selected using the widely compatible legume Vigna unguiculata. Plant Mol Biol. 1987;8(6):447-59doi: 10.1007/BF00017990.
Lewin, A., Rosenberg, C., H Meyer, Z. A., Wong, C. H., Nelson, L., Manen, J. F., Stanley, J., Dowling, D. N., Denarie, J., & Broughton, W. J. (1987). Multiple host-specificity loci of the broad host-range Rhizobium sp. NGR234 selected using the widely compatible legume Vigna unguiculata. Plant molecular biology, 8(6), 447-59. https://doi.org/10.1007/BF00017990
Lewin, A, et al. "Multiple host-specificity loci of the broad host-range Rhizobium sp. NGR234 selected using the widely compatible legume Vigna unguiculata." Plant molecular biology vol. 8,6 (1987): 447-59. doi: https://doi.org/10.1007/BF00017990
Lewin A, Rosenberg C, H Meyer ZA, Wong CH, Nelson L, Manen JF, Stanley J, Dowling DN, Denarie J, Broughton WJ. Multiple host-specificity loci of the broad host-range Rhizobium sp. NGR234 selected using the widely compatible legume Vigna unguiculata. Plant Mol Biol. 1987 Nov;8(6):447-59. doi: 10.1007/BF00017990. PMID: 24301307.
Copy Download .nbib Format: NLM
Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development.

JIMD reports

Shelihan I, Rossignol E, Décarie JC, Bonnefont JP, Brivet M, Brunel-Guitton C, Mitchell GA.
PMID: 35028265
JIMD Rep. 2021 Sep 29;63(1):3-10. doi: 10.1002/jmd2.12243. eCollection 2022 Jan.

OBJECTIVE: To report an adolescent with infantile-onset carnitine palmitoyltransferase 2 (CPT2) deficiency and cerebral malformations and to review the occurrence of brain malformations in CPT2 deficiency. The patient presented clinically at age 5 months with dehydration and hepatomegaly. He...

Cite
Shelihan I, Rossignol E, Décarie JC, et al. Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development. JIMD Rep. 2021;63(1):3-10doi: 10.1002/jmd2.12243.
Shelihan, I., Rossignol, E., Décarie, J. C., Bonnefont, J. P., Brivet, M., Brunel-Guitton, C., & Mitchell, G. A. (2022). Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development. JIMD reports, 63(1), 3-10. https://doi.org/10.1002/jmd2.12243
Shelihan, Ivan, et al. "Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development." JIMD reports vol. 63,1 (2022): 3-10. doi: https://doi.org/10.1002/jmd2.12243
Shelihan I, Rossignol E, Décarie JC, Bonnefont JP, Brivet M, Brunel-Guitton C, Mitchell GA. Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development. JIMD Rep. 2021 Sep 29;63(1):3-10. doi: 10.1002/jmd2.12243. eCollection 2022 Jan. PMID: 35028265; PMCID: PMC8743346.
Copy Download .nbib Format: NLM
Childhood Burkitt lymphoma manifesting as cavernous sinus syndrome.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie

Jakubowska W, Chorfi S, Bélanger C, Décarie JC, Ospina LH.
PMID: 34384741
Can J Ophthalmol. 2021 Aug 09; doi: 10.1016/j.jcjo.2021.06.003. Epub 2021 Aug 09.

No abstract available.

Cite
Jakubowska W, Chorfi S, Bélanger C, et al. Childhood Burkitt lymphoma manifesting as cavernous sinus syndrome. Can J Ophthalmol. 2021;doi: 10.1016/j.jcjo.2021.06.003.
Jakubowska, W., Chorfi, S., Bélanger, C., Décarie, J. C., & Ospina, L. H. (2021). Childhood Burkitt lymphoma manifesting as cavernous sinus syndrome. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, . https://doi.org/10.1016/j.jcjo.2021.06.003
Jakubowska, Weronika, et al. "Childhood Burkitt lymphoma manifesting as cavernous sinus syndrome." Canadian journal of ophthalmology. Journal canadien d'ophtalmologie vol. (2021). doi: https://doi.org/10.1016/j.jcjo.2021.06.003
Jakubowska W, Chorfi S, Bélanger C, Décarie JC, Ospina LH. Childhood Burkitt lymphoma manifesting as cavernous sinus syndrome. Can J Ophthalmol. 2021 Aug 09; doi: 10.1016/j.jcjo.2021.06.003. Epub 2021 Aug 09. PMID: 34384741.
Copy Download .nbib Format: NLM
Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development.

JIMD reports

Shelihan I, Rossignol E, Décarie JC, Bonnefont JP, Brivet M, Brunel-Guitton C, Mitchell GA.
PMID: 35028265
JIMD Rep. 2021 Sep 29;63(1):3-10. doi: 10.1002/jmd2.12243. eCollection 2022 Jan.

OBJECTIVE: To report an adolescent with infantile-onset carnitine palmitoyltransferase 2 (CPT2) deficiency and cerebral malformations and to review the occurrence of brain malformations in CPT2 deficiency. The patient presented clinically at age 5 months with dehydration and hepatomegaly. He...

Cite
Shelihan I, Rossignol E, Décarie JC, et al. Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development. JIMD Rep. 2021;63(1):3-10doi: 10.1002/jmd2.12243.
Shelihan, I., Rossignol, E., Décarie, J. C., Bonnefont, J. P., Brivet, M., Brunel-Guitton, C., & Mitchell, G. A. (2022). Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development. JIMD reports, 63(1), 3-10. https://doi.org/10.1002/jmd2.12243
Shelihan, Ivan, et al. "Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development." JIMD reports vol. 63,1 (2022): 3-10. doi: https://doi.org/10.1002/jmd2.12243
Shelihan I, Rossignol E, Décarie JC, Bonnefont JP, Brivet M, Brunel-Guitton C, Mitchell GA. Infantile onset carnitine palmitoyltransferase 2 deficiency: Cortical polymicrogyria, schizencephaly, and gray matter heterotopias in an adolescent with normal development. JIMD Rep. 2021 Sep 29;63(1):3-10. doi: 10.1002/jmd2.12243. eCollection 2022 Jan. PMID: 35028265; PMCID: PMC8743346.
Copy Download .nbib Format: NLM
Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A .

Frontiers in pediatrics

Beghetti M, Berger RMF, Bonnet D, Grill S, Lesage C, Lemarie JC, Ivy DD.
PMID: 34222150
Front Pediatr. 2021 Jun 16;9:681538. doi: 10.3389/fped.2021.681538. eCollection 2021.

FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion (FUTURE) 3 was a 24-week open-label, prospective, and randomized phase 3 study that assessed the pharmacokinetics of bosentan 2 mg/kg b.i.d. or t.i.d. in children with pulmonary arterial hypertension (PAH). We report...

Cite
Beghetti M, Berger RMF, Bonnet D, et al. Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A . Front Pediatr. 2021;9:681538doi: 10.3389/fped.2021.681538.
Beghetti, M., Berger, R. M. F., Bonnet, D., Grill, S., Lesage, C., Lemarie, J. C., & Ivy, D. D. (2021). Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A . Frontiers in pediatrics, 9681538. https://doi.org/10.3389/fped.2021.681538
Beghetti, Maurice, et al. "Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A ." Frontiers in pediatrics vol. 9 (2021): 681538. doi: https://doi.org/10.3389/fped.2021.681538
Beghetti M, Berger RMF, Bonnet D, Grill S, Lesage C, Lemarie JC, Ivy DD. Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A . Front Pediatr. 2021 Jun 16;9:681538. doi: 10.3389/fped.2021.681538. eCollection 2021. PMID: 34222150; PMCID: PMC8242164.
Copy Download .nbib Format: NLM
RESPONSE: re: prognostic importance of low c-erbB2 expression in breast tumors .

Journal of the National Cancer Institute

Koscielny S, Terrier P, Spielmann M, Delarue JC.
PMID: 10491438
J Natl Cancer Inst. 1999 Sep 15;91(18):1585. doi: 10.1093/jnci/91.18.1585.

No abstract available.

Cite
Koscielny S, Terrier P, Spielmann M, et al. RESPONSE: re: prognostic importance of low c-erbB2 expression in breast tumors . J Natl Cancer Inst. 1999;91(18):1585doi: 10.1093/jnci/91.18.1585.
Koscielny, S., Terrier, P., Spielmann, M., & Delarue, J. C. (1999). RESPONSE: re: prognostic importance of low c-erbB2 expression in breast tumors . Journal of the National Cancer Institute, 91(18), 1585. https://doi.org/10.1093/jnci/91.18.1585
Koscielny, et al. "RESPONSE: re: prognostic importance of low c-erbB2 expression in breast tumors ." Journal of the National Cancer Institute vol. 91,18 (1999): 1585. doi: https://doi.org/10.1093/jnci/91.18.1585
Koscielny S, Terrier P, Spielmann M, Delarue JC. RESPONSE: re: prognostic importance of low c-erbB2 expression in breast tumors . J Natl Cancer Inst. 1999 Sep 15;91(18):1585. doi: 10.1093/jnci/91.18.1585. PMID: 10491438.
Copy Download .nbib Format: NLM
Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion.

Journal of the American Heart Association

Turner S, Voogt J, Davidson M, Glass A, Killion S, Decaris J, Mohammed H, Minehira K, Boban D, Murphy E, Luchoomun J, Awada M, Neese R, Hellerstein M.
PMID: 23130164
J Am Heart Assoc. 2012 Aug;1(4):e001826. doi: 10.1161/JAHA.112.001826. Epub 2012 Aug 24.

BACKGROUND: Reverse cholesterol transport from peripheral tissues is considered the principal atheroprotective mechanism of high-density lipoprotein, but quantifying reverse cholesterol transport in humans in vivo remains a challenge. We describe here a method for measuring flux of cholesterol though...

Cite
Turner S, Voogt J, Davidson M, et al. Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc. 2012;1(4):e001826doi: 10.1161/JAHA.112.001826.
Turner, S., Voogt, J., Davidson, M., Glass, A., Killion, S., Decaris, J., Mohammed, H., Minehira, K., Boban, D., Murphy, E., Luchoomun, J., Awada, M., Neese, R., & Hellerstein, M. (2012). Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. Journal of the American Heart Association, 1(4), e001826. https://doi.org/10.1161/JAHA.112.001826
Turner, Scott, et al. "Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion." Journal of the American Heart Association vol. 1,4 (2012): e001826. doi: https://doi.org/10.1161/JAHA.112.001826
Turner S, Voogt J, Davidson M, Glass A, Killion S, Decaris J, Mohammed H, Minehira K, Boban D, Murphy E, Luchoomun J, Awada M, Neese R, Hellerstein M. Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc. 2012 Aug;1(4):e001826. doi: 10.1161/JAHA.112.001826. Epub 2012 Aug 24. PMID: 23130164; PMCID: PMC3487360.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries